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Abstract
Introduction—Plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory
marker associated positively with atherothrombotic risk. Whether Lp-PLA2 is related to risk of
venous thromboembolism (VTE) is incompletely studied.
Methods—We assessed Lp-PLA2 activity in 10,687 Atherosclerosis Risk in Communities
(ARIC) Study participants and followed them a median of 8.3 years (from 1996–98 through 2005)
for VTE occurrence (n = 226).
Results—There was no significant association between baseline Lp-PLA2 quartiles and risk of
VTE, neither overall nor stratified as provoked or unprovoked. Adjusted for other risk factors, the
hazard ratios (95% confidence interval) of total VTE across quartiles of Lp-PLA2 were 1.0
(reference), 0.95 (0.64, 1.42), 1.03 (0.69, 1.56), and 1.26 (0.83, 1.91). In the subset of participants
with LDL-cholesterol ≥ 130 mg/dL, hazard ratios of total VTE were 1.00, 1.39 (0.44, 4.44), 2.45
(0.84, 7.11), and 2.84 (0.99, 8.14).
Conclusion—Our study does not support the overall hypothesis that elevated Lp-PLA2
contributes to VTE occurrence in the general population. However, in the presence of high LDL-
cholesterol there was some evidence that Lp-PLA2 may increase VTE risk.
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Plasma lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet
activating factor acetylhydrolase, is produced by inflammatory cells, co-travels with low-
density lipoprotein (LDL), and hydrolyzes oxidized phospholipids, thereby propagating
inflammation and potentially thrombosis [1]. Prospective epidemiologic studies have
consistently associated elevated Lp-PLA2 (e.g., above the highest tertile) with increased risk
of atherothrombotic events [2–5]. The hypothesized mechanism for Lp-PLA2 elevating
atherothrombotic risk is the generation of bioactive lipids that elicit an arterial inflammatory
response [6].
Just one study, with only 129 incident elderly VTE cases, has examined whether elevated
Lp-PLA2 is associated with increased risk of VTE [7]. It found no relation of plasma Lp-
PLA2 activity or mass with VTE incidence. We hypothesized that a positive association
exists between Lp-PLA2 activity and VTE in a cohort of white and African American adults.
Methods
In 1987–89, the ARIC Study recruited to an initial examination a cohort of 15,792 men and
women aged 45–64 years from four U.S. communities [8]. Participants were re-examined in
1990–92 (93% response), 1993–95 (86%) and 1996–98 (80%), and followed long-term for
cardiovascular events. Participants in ARIC Visit 4 serve as the cohort for the present
analysis.
ARIC assessed Lp-PLA2 activity in Visit 4 plasma by an automated Colorimetric Activity
Method (CAM) assay (diaDexus Inc., South San Francisco, CA) using a Beckman Coulter
(Olympus) AU400e autoanalyzer. The Lp-PLA2 activity assay had an inter-assay variation
coefficient of 4.4% and a reliability coefficient (R) of 0.92, based on 419 blinded replicate
samples. ARIC also measured cystatin C (N Latex Cystatin C, Dade Behring, Inc.,
Deerfield, IL) to estimate glomerular filtration rate (eGFR) [9], and assessed plasma C-
reactive protein (CRP) by the CRP-Latex (II) high sensitivity assay from Denka Seiken
(Tokyo, Japan). ARIC did not measure factor VIIIc or activated partial thromboplastin time
(aPTT) at Visit 4, so Visit 1 values were used [10,11].
ARIC followed participants through 2005 to identify hospitalized VTE events. Physician-
reviewers validated VTEs using a standardized protocol involving review of medical records
and imaging reports [12]. Reviewers also subcategorized VTEs as unprovoked or provoked
(occurring within 90 days of major trauma, surgery, marked immobility, active cancer or
chemotherapy) [12].
From the 11,656 participants at Visit 4, we excluded from analyses 342 who had a prior
history of VTE, 191 who were taking warfarin, 31 non-white or non-African American
participants, 403 with missing Lp-PLA2 values, and two Lp-PLA2 outliers. Our final
analytic sample comprised 10,687 participants -- 8328 whites, 2359 African Americans.
Follow-up time ended when the participant had a VTE, died, was lost to follow-up, or
survived until 31 December 2005.
We used Cox proportional hazards regression to model the association between quartiles of
baseline (Visit 4) Lp-PLA2 and VTE incidence and to derive hazard ratios and 95% CI. We
tested the trend in hazard ratios using an ordinal variable to designate each quartile. In a
secondary analysis, we also examined the VTE association using Lp-PLA2 as a continuous
variable. The proportional hazards assumption was tested for total, provoked, and
unprovoked VTE models by including time by Lp-PLA2 interaction terms. The p-value for
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this proportionality test ranged from 0.02 to 0.11, and analyses stratified by time suggested
Lp-PLA2 might be positively associated with VTE in the first five years of follow-up and
negatively during later follow-up. However, in neither period was the p-trend for the
association statistically significant. Therefore, we chose to present time-unstratified results.
Covariates in the models included VTE risk factors measured in the whole ARIC cohort at
Visit 4 [10,11,13,15] as well as LDL-cholesterol and statin use. Adjustment for factor VIIIc
and aPTT (measured at Visit 1) had no impact, so they were dropped from models.
Smoking, physical activity, and hypertension were not VTE risk factors in ARIC [13].
Results
In this sample of 10,687 ARIC Visit 4 participants aged 53–75 years, with no history of
VTE and not using warfarin, plasma Lp-PLA2 activity was quite normally distributed with a
mean ± SD of 229 ± 62 nmol/min/mL. As reported by others [7,14], Lp-PLA2 varied
markedly by sex and race. Quartile cutpoints for Lp-PLA2 in nmol/min/mL were: 176, 207,
and 242 for white women; 234, 267, and 302 for white men; 147, 178, and 213 for African
American women; and 188, 220, and 260 for African American men. We therefore
conducted the quartile analyses using sex-race specific quartile cutpoints.
Baseline Lp-PLA2 was strongly positively correlated with LDL-cholesterol but relatively
weakly correlated with the VTE risk factors examined (Table 1). Over a median of 8.3 years
of follow-up, we identified 226 VTEs (146 provoked, 80 unprovoked). As reflected by
hazard ratios near 1.0 (Table 2), there was little evidence that sex-race specific plasma Lp-
PLA2 activity was an independent risk factor for VTE. Results were largely the same when
repeated using overall, rather than sex-race specific, quartile cutpoints (not shown). When
treated as a continuous variable, the hazard ratio of total VTE per one standard deviation
greater level of Lp-PLA2 [1.12 (95% CI = 0.94, 1.34)] was nonsignificant (p=0.22), with
Model 2 adjustment.
In Model 2 for total VTE, we tested interactions of (a) Lp-PLA2 by hormone replacement
therapy and (b) Lp-PLA2 by LDL-cholesterol. Neither was statistically significant (p>0.25).
Nevertheless, because of potential biological interaction between Lp-PLA2 and LDL-
cholesterol, we examined Lp-PLA2 associations with VTE, after stratifying participants into
two LDL-cholesterol groups (<130 mg/dL or ≥ 130 mg/dL). As shown in Table 3, Lp-PLA2
was associated positively with VTE in participants with high LDL-cholesterol. However,
this was based on small numbers of participants and VTEs within the subgroups, especially
in the reference category with high LDL cholesterol and low Lp-PLA2.
Discussion
In this prospective cohort, greater baseline Lp-PLA2 activity was not associated overall with
an increased incidence of VTE. This contrasts with another inflammatory marker, C-reactive
protein, which was associated positively with VTE incidence in this cohort [15]. The lack of
an overall association with VTE also contrasts with the consistently reported positive
association of Lp-PLA2 with atherothrombotic events [2–5].
Lp-PLA2 is a lipid-hydrolyzing enzyme associating primarily with LDL, and LDL could
serve as an Lp-PLA2 substrate [1]. Upon stratification by LDL-cholesterol level, Lp-PLA2
seemed to be associated positively with VTE occurrence among participants with high LDL-
cholesterol. This finding should be viewed with caution because it was a secondary stratified
analysis with limited VTE events, and the formal test for statistical interaction between Lp-
PLA2 and LDL-cholesterol was not significant. Yet, it is consistent with higher VTE risk in
the setting of both high Lp-PLA2 and LDL-cholesterol.
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Strengths of this study include the moderately large population based biracial sample and the
careful risk factor and VTE outcome measures. Drawbacks include (1) the single measure of
Lp-PLA2 activity, (2) no measure of Lp-PLA2 mass, (3) a sample size that cannot rule out a
weak, true association, (4) the relatively long follow-up during which Lp-PLA2 may have
changed, and (5) insufficient data to stratify results by common thrombophilia markers (e.g.,
Factor V Leiden or prothrombin G20210A) in the full ARIC cohort. It is also remotely
possible that an Lp-PLA2 association with VTE may have been masked by not having Visit
4 data to allow adjustment for diet and physical activity.
In conclusion, our findings, along with one prior study [7], suggest that baseline Lp-PLA2 is
not associated to any significant extent with risk of VTE in the general population.
However, further exploration is warranted on whether Lp-PLA2 may be a VTE risk factor in
adults with high LDL-cholesterol.
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